This company listing is no longer active
MGC Pharmaceuticals Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
MGC Pharmaceuticals's earnings have been declining at an average annual rate of -17.9%, while the Pharmaceuticals industry saw earnings growing at 31.2% annually. Revenues have been growing at an average rate of 36% per year.
Anahtar bilgiler
-17.9%
Kazanç büyüme oranı
2.0%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 31.2% |
| Gelir büyüme oranı | 36.0% |
| Özkaynak getirisi | n/a |
| Net Marj | -614.7% |
| Son Kazanç Güncellemesi | 30 Jun 2023 |
Yakın geçmiş performans güncellemeleri
Güncelleme yok
Recent updates
Gelir ve Gider Dağılımı
MGC Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 23 | 3 | -21 | 15 | 0 |
| 31 Mar 23 | 4 | -22 | 15 | 0 |
| 31 Dec 22 | 5 | -23 | 15 | 0 |
| 30 Sep 22 | 5 | -22 | 13 | 0 |
| 30 Jun 22 | 5 | -20 | 12 | 0 |
| 31 Mar 22 | 5 | -19 | 11 | 0 |
| 31 Dec 21 | 5 | -18 | 10 | 0 |
| 30 Sep 21 | 4 | -17 | 9 | 0 |
| 30 Jun 21 | 3 | -16 | 8 | 0 |
| 31 Dec 20 | 1 | -13 | 5 | 0 |
| 30 Sep 20 | 2 | -16 | 6 | 0 |
| 30 Jun 20 | 2 | -19 | 7 | 0 |
| 31 Dec 19 | 2 | -18 | 7 | -1 |
| 30 Sep 19 | 1 | -14 | 6 | 0 |
| 30 Jun 19 | 1 | -11 | 6 | 0 |
| 31 Dec 18 | 1 | -7 | 5 | 1 |
| 30 Sep 18 | 0 | -7 | 5 | 1 |
| 30 Jun 18 | 0 | -8 | 5 | 1 |
| 31 Mar 18 | 0 | -10 | 6 | 1 |
| 31 Dec 17 | 0 | -12 | 6 | 0 |
| 30 Sep 17 | 0 | -10 | 6 | 0 |
| 30 Jun 17 | 0 | -8 | 7 | 0 |
| 31 Mar 17 | 0 | -7 | 5 | 0 |
| 31 Dec 16 | 0 | -6 | 4 | 0 |
| 30 Sep 16 | 0 | -6 | 3 | 0 |
| 30 Jun 16 | 0 | -6 | 2 | 0 |
| 31 Mar 16 | 0 | -6 | 2 | 0 |
| 31 Dec 15 | 0 | -6 | 1 | 0 |
| 30 Sep 15 | 0 | -5 | 1 | 0 |
| 30 Jun 15 | 0 | -4 | 1 | 0 |
| 31 Mar 15 | 0 | -5 | 1 | 0 |
| 31 Dec 14 | 0 | -6 | 1 | 0 |
| 30 Sep 14 | 0 | -6 | 1 | 0 |
| 30 Jun 14 | 0 | -5 | 0 | 0 |
| 31 Mar 14 | 0 | -3 | 0 | 0 |
| 31 Dec 13 | 0 | 0 | 0 | 0 |
| 30 Sep 13 | 0 | -1 | 0 | 0 |
| 30 Jun 13 | 0 | -1 | 1 | 0 |
| 31 Mar 13 | 0 | -1 | 0 | 0 |
| 31 Dec 12 | 0 | -1 | 0 | 0 |
Kaliteli Kazançlar: MXCDA is currently unprofitable.
Büyüyen Kar Marjı: MXCDA is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: MXCDA is unprofitable, and losses have increased over the past 5 years at a rate of 17.9% per year.
Büyüme Hızlandırma: Unable to compare MXCDA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: MXCDA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10%).
Özkaynak Getirisi
Yüksek ROE: MXCDA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.